Cell and gene therapy represents the most transformative therapeutic modality in modern medicine — offering the potential for single-administration curative treatment for genetic and oncological diseases. The FDA has approved over 30 cell and gene therapies, with CAR-T cell therapies for hematological malignancies, AAV gene therapies for rare genetic diseases, and CRISPR-based gene editing therapies representing the three primary modalities. Vertex and CRISPR Therapeutics' CASGEVY — approved in 2023 for sickle cell disease and beta-thalassemia — is the first approved CRISPR therapy, establishing gene editing as a clinical reality.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• CAR-T Cell Therapy Market
• AAV Gene Therapy Programs
• CRISPR Gene Editing — CASGEVY and Pipeline
• Manufacturing Challenges
• Reimbursement and Access
• Takeda, Biogen, and Competitor Programs
• Next-Generation Cell Therapy
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. CAR-T Cell Therapy Market
4. AAV Gene Therapy Programs
5. CRISPR Gene Editing — CASGEVY and Pipeline
6. Manufacturing Challenges
7. Reimbursement and Access
8. Takeda, Biogen, and Competitor Programs
9. Next-Generation Cell Therapy
10. Competitive Landscape
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Pipeline Assessment 2025
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Spark Therapeutics
BioMarin
Sarepta
bluebird bio
Ultragenyx
Novartis Gene Therapies
Regenxbio
